<p>隨着澳大利亞市場逐漸接近假期季節，市場出現了輕微下滑，這主要歸因於在主要全球指數接近歷史高點時的獲利了結。在這種背景下，澳大利亞的高增長科技股為尋求創新和潛在擴張的投資者提供了引人注目的機會，特別是當這些公司在波動的經濟條件下展現出韌性和適應能力時。</p>
<h3>澳大利亞十大高增長科技公司</h3>
<table>
<thead>
<tr>
<th>名稱</th>
<th>收入增長</th>
<th>盈利增長</th>
<th>增長評級</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pureprofile</td>
<td>10.51%</td>
<td>37.56%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Pro Medicus</td>
<td>19.70%</td>
<td>21.17%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Kinatico</td>
<td>13.27%</td>
<td>42.29%</td>
<td>★★★★☆☆</td>
</tr>
<tr>
<td>Clinuvel Pharmaceuticals</td>
<td>22.02%</td>
<td>23.88%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>BlinkLab</td>
<td>104.90%</td>
<td>101.40%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Xero</td>
<td>18.02%</td>
<td>24.83%</td>
<td>★★★★☆☆</td>
</tr>
<tr>
<td>Wrkr</td>
<td>35.94%</td>
<td>53.22%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Artrya</td>
<td>50.54%</td>
<td>61.25%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Ai-Media Technologies</td>
<td>16.83%</td>
<td>94.47%</td>
<td>★★★★☆☆</td>
</tr>
<tr>
<td>FINEOS Corporation Holdings</td>
<td>9.22%</td>
<td>57.85%</td>
<td>★★★★☆☆</td>
</tr>
</tbody>
</table>
<p>點擊這裏查看我們 ASX 高增長科技和人工智能股票篩選器中的 22 只股票的完整列表。</p>
<p>在這裏，我們突出了一些我們偏好的股票。</p>
<h2>FINEOS Corporation Holdings (ASX:FCL)</h2>
<p><strong>Simply Wall St 增長評級：</strong> ★★★★☆☆</p>
<p><strong>概述：</strong> FINEOS Corporation Holdings plc 開發並銷售企業索賠和保單管理軟件，服務於北美、亞太、中東和非洲的壽險、意外險和健康險公司以及員工福利提供商；其市值約為 10.3 億澳元。</p>
<p><strong>運營：</strong> FINEOS 主要通過其軟件和編程部門產生收入，金額為 1.359 億歐元。該公司專注於為各個地區的保險公司和福利提供商提供專業軟件解決方案。</p>
<p>FINEOS Corporation Holdings 在澳大利亞的高增長科技領域中獨樹一幟，年收入增長率達到 9.2%。儘管目前尚未盈利，但該公司對保險行業軟件解決方案的戰略關注，體現了其在三年內實現盈利的強大計劃，預計年盈利增長率將達到 57.85%。最近的高管變動旨在進一步提升治理和市場戰略，Michael Kelly 轉任執行董事長，並引入了行業資深專業人士如 Stephen Devine 加入董事會。這一領導層的更新有望在競爭壓力中激勵 FINEOS 的發展軌跡，可能加速其實現正現金流和超越市場表現的進程。</p>
<ul>
<li>點擊這裏訪問我們的完整健康分析報告，以瞭解 FINEOS Corporation Holdings 的動態。</li>
<li>瞭解 FINEOS Corporation Holdings 的歷史表現。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/e94d8063-92b0-4417-ae8a-08facdd76595/chart/revenue-and-expenses-breakdown?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/e94d8063-92b0-4417-ae8a-08facdd76595/chart/revenue-and-expenses-breakdown"/></p>
<p>截至 2025 年 12 月的 ASX:FCL 收入和支出明細</p>
<h2>PYC Therapeutics (ASX:PYC)</h2>
<p><strong>Simply Wall St 增長評級：</strong> ★★★★☆☆</p>
<p><strong>概述：</strong> PYC Therapeutics Limited 是一家藥物開發公司，專注於為澳大利亞的遺傳疾病開發基於 RNA 的治療，其市值為 9.5655 億澳元。</p>
<p><strong>運營：</strong> 該公司通過專注於新型 RNA 治療的發現和開發來產生收入，報告收入為 2349 萬澳元。</p>
<p>PYC Therapeutics 在經歷了一個充滿挑戰的階段，預計未來三年收入將年縮減 5.8%，但對未來盈利仍持樂觀態度，預計年盈利增長為 27.6%。這與其當前的虧損狀態和去年經歷的股東稀釋形成鮮明對比。最近的戰略董事會變動，包括任命 Peter Coleman 為獨立非執行主席，強調了利用其併購專業知識引導 PYC 實現預期的 22.8% 強勁股本回報的承諾。這些舉措對 PYC 逆轉負面趨勢並在生物科技領域抓住增長機會至關重要。</p>
<ul>
<li>在這份健康報告中解鎖我們對 PYC Therapeutics 股票分析的全面見解。</li>
<li>通過我們的歷史報告獲取 PYC Therapeutics 的過去趨勢和表現的見解。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/3e24207c-efd2-40eb-8d28-87ef9ac565d7/chart/earnings-and-revenue-growth?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/3e24207c-efd2-40eb-8d28-87ef9ac565d7/chart/earnings-and-revenue-growth"/></p>
<p>截至 2025 年 12 月的 ASX:PYC 盈利和收入增長</p>
<h2>RPMGlobal Holdings (ASX:RUL)</h2>
<p><strong>Simply Wall St 增長評級：</strong> ★★★★☆☆</p>
<p><strong>概述：</strong> RPMGlobal Holdings Limited 開發並提供礦業軟件解決方案，覆蓋澳大利亞、亞洲、美洲、非洲和歐洲等多個地區，市值約為 11 億澳元。</p>
<p><strong>運營：</strong> RPMGlobal Holdings 主要通過其軟件部門產生收入，金額為 7396 萬澳元，而諮詢部門貢獻 2477 萬澳元。</p>
<p>RPMGlobal Holdings 預計年收入增長 15%，盈利激增 55%，顯著超過澳大利亞市場平均水平。儘管利潤率從去年的 5.3% 小幅收縮至 0.01%，但該公司對礦業創新軟件解決方案的戰略關注可能推動未來盈利。最近的股東會議強調了與 Caterpillar 的批准計劃，可能增強 RPMGlobal 的市場地位和運營範圍，使其在澳大利亞科技領域成為一個值得關注的競爭者，儘管去年財務波動中出現了 220 萬澳元的一次性損失。</p>
<ul>
<li>點擊這裏通過我們的詳細分析健康報告發現 RPMGlobal Holdings 的細微差別。</li>
<li>通過訪問我們的歷史表現報告評估 RPMGlobal Holdings 的歷史表現。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/ab8df570-d416-497d-a9f1-5b7dd287a345/chart/earnings-and-revenue-growth?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/ab8df570-d416-497d-a9f1-5b7dd287a345/chart/earnings-and-revenue-growth"/></p>
<p>ASX:RUL 截至 2025 年 12 月的收益和收入增長</p>
<h2>下一步</h2>
<ul>
<li>點擊這裏深入瞭解 22 只 ASX 高增長科技和人工智能股票的全貌。</li>
<li>你是否已經將投資組合多樣化到這些公司？利用 Simply Wall St 的投資組合功能，密切關注影響你投資的市場動態。</li>
<li>使用 Simply Wall St 應用程序提升你的投資能力，享受免費訪問覆蓋每個大洲的市場情報。</li>
</ul>
<h2>對其他可能性感興趣？</h2>
<ul>
<li>探索尚未獲得顯著分析師關注的高表現小型公司。</li>
<li>用顯示強勁增長潛力的公司充實你的投資組合，這些公司得到了分析師和管理層的樂觀展望支持。</li>
<li>尋找現金流潛力良好但交易價格低於其公允價值的公司。</li>
</ul>
<p><em>這篇文章由 Simply Wall St 撰寫，內容具有一般性。<strong>我們提供基於歷史數據和分析師預測的評論，僅使用無偏見的方法，我們的文章並不構成財務建議。</strong> 它不構成買入或賣出任何股票的推薦，也未考慮你的目標或財務狀況。我們的目標是為你提供以基本數據驅動的長期分析。請注意，我們的分析可能未考慮最新的價格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中沒有持倉。</em></p>
<p>移動基礎設施用於國防和災難</p>
<p>下一波機器人技術不是類人型的。它是完全自主的塔樓，在 30 分鐘內提供 5G、ISR 和雷達服務，覆蓋任何地方。</p>
<p>在下一輪合同之前獲取投資者簡報</p>
<p>代表 CiTech 贊助</p>

<p>澳大利亞市場在全球指數創下歷史新高之際，出現了輕微下跌，投資者進行獲利了結。高增長的科技股為投資者提供了機會。值得注意的公司包括 FINEOS Corporation Holdings、PYC Therapeutics 和 RPMGlobal Holdings，這些公司均顯示出良好的增長率和旨在提升盈利能力的戰略變化。FINEOS 專注於保險軟件，PYC 專注於基於 RNA 的治療，RPMGlobal 則專注於礦業軟件解決方案。儘管面臨當前挑戰，這些公司在未來有潛在的擴張和改善財務表現的機會</p>

<p>As the Australian market edges towards the holiday season, it is experiencing a slight dip, largely attributed to profit-taking as major global indices approach record highs. In this context, high growth tech stocks in Australia can offer intriguing opportunities for investors seeking innovation and potential expansion, particularly when these companies demonstrate resilience and adaptability amidst fluctuating economic conditions.</p>
<div class="lb-trans"><p>隨着澳大利亞市場逐漸接近假期季節，市場出現了輕微下滑，這主要歸因於在主要全球指數接近歷史高點時的獲利了結。在這種背景下，澳大利亞的高增長科技股為尋求創新和潛在擴張的投資者提供了引人注目的機會，特別是當這些公司在波動的經濟條件下展現出韌性和適應能力時。</p>
</div><h3>Top 10 High Growth Tech Companies In Australia</h3>
<div class="lb-trans"><h3>澳大利亞十大高增長科技公司</h3>
</div><table>
<thead>
<tr>
<th>Name</th>
<th>Revenue Growth</th>
<th>Earnings Growth</th>
<th>Growth Rating</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pureprofile</td>
<td>10.51%</td>
<td>37.56%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Pro Medicus</td>
<td>19.70%</td>
<td>21.17%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Kinatico</td>
<td>13.27%</td>
<td>42.29%</td>
<td>★★★★☆☆</td>
</tr>
<tr>
<td>Clinuvel Pharmaceuticals</td>
<td>22.02%</td>
<td>23.88%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>BlinkLab</td>
<td>104.90%</td>
<td>101.40%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Xero</td>
<td>18.02%</td>
<td>24.83%</td>
<td>★★★★☆☆</td>
</tr>
<tr>
<td>Wrkr</td>
<td>35.94%</td>
<td>53.22%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Artrya</td>
<td>50.54%</td>
<td>61.25%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Ai-Media Technologies</td>
<td>16.83%</td>
<td>94.47%</td>
<td>★★★★☆☆</td>
</tr>
<tr>
<td>FINEOS Corporation Holdings</td>
<td>9.22%</td>
<td>57.85%</td>
<td>★★★★☆☆</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th>名稱</th>
<th>收入增長</th>
<th>盈利增長</th>
<th>增長評級</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pureprofile</td>
<td>10.51%</td>
<td>37.56%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Pro Medicus</td>
<td>19.70%</td>
<td>21.17%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Kinatico</td>
<td>13.27%</td>
<td>42.29%</td>
<td>★★★★☆☆</td>
</tr>
<tr>
<td>Clinuvel Pharmaceuticals</td>
<td>22.02%</td>
<td>23.88%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>BlinkLab</td>
<td>104.90%</td>
<td>101.40%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Xero</td>
<td>18.02%</td>
<td>24.83%</td>
<td>★★★★☆☆</td>
</tr>
<tr>
<td>Wrkr</td>
<td>35.94%</td>
<td>53.22%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Artrya</td>
<td>50.54%</td>
<td>61.25%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Ai-Media Technologies</td>
<td>16.83%</td>
<td>94.47%</td>
<td>★★★★☆☆</td>
</tr>
<tr>
<td>FINEOS Corporation Holdings</td>
<td>9.22%</td>
<td>57.85%</td>
<td>★★★★☆☆</td>
</tr>
</tbody>
</table>
</div><p>Click here to see the full list of 22 stocks from our ASX High Growth Tech and AI Stocks screener.</p>
<div class="lb-trans"><p>點擊這裏查看我們 ASX 高增長科技和人工智能股票篩選器中的 22 只股票的完整列表。</p>
</div><p>Here we highlight a subset of our preferred stocks from the screener.</p>
<div class="lb-trans"><p>在這裏，我們突出了一些我們偏好的股票。</p>
</div><h2>FINEOS Corporation Holdings (ASX:FCL)</h2>
<div class="lb-trans"><h2>FINEOS Corporation Holdings (ASX:FCL)</h2>
</div><p><strong>Simply Wall St Growth Rating:</strong> ★★★★☆☆</p>
<div class="lb-trans"><p><strong>Simply Wall St 增長評級：</strong> ★★★★☆☆</p>
</div><p><strong>Overview:</strong> FINEOS Corporation Holdings plc develops and sells enterprise claims and policy management software for life, accident, and health insurers as well as employee benefits providers across North America, the Asia Pacific, the Middle East, and Africa; it has a market capitalization of approximately A$1.03 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> FINEOS Corporation Holdings plc 開發並銷售企業索賠和保單管理軟件，服務於北美、亞太、中東和非洲的壽險、意外險和健康險公司以及員工福利提供商；其市值約為 10.3 億澳元。</p>
</div><p><strong>Operations:</strong> FINEOS generates revenue primarily from its software and programming segment, amounting to €135.90 million. The company focuses on providing specialized software solutions for insurers and benefits providers across various regions.</p>
<div class="lb-trans"><p><strong>運營：</strong> FINEOS 主要通過其軟件和編程部門產生收入，金額為 1.359 億歐元。該公司專注於為各個地區的保險公司和福利提供商提供專業軟件解決方案。</p>
</div><p>FINEOS Corporation Holdings has positioned itself distinctively in the high-growth tech sector of Australia, with a notable annual revenue growth rate of 9.2%. Despite its current unprofitability, the company's strategic focus on software solutions for the insurance industry is underscored by robust plans for profitability within three years, reflecting an impressive expected earnings growth of 57.85% annually. Recent executive changes aim to further enhance governance and market strategy, as evidenced by Michael Kelly transitioning to Executive Chairman and the introduction of seasoned industry professionals like Stephen Devine to its Board. This leadership refresh promises to invigorate FINEOS’s trajectory amidst competitive pressures, potentially accelerating its journey towards positive cash flows and above-market performance.</p>
<div class="lb-trans"><p>FINEOS Corporation Holdings 在澳大利亞的高增長科技領域中獨樹一幟，年收入增長率達到 9.2%。儘管目前尚未盈利，但該公司對保險行業軟件解決方案的戰略關注，體現了其在三年內實現盈利的強大計劃，預計年盈利增長率將達到 57.85%。最近的高管變動旨在進一步提升治理和市場戰略，Michael Kelly 轉任執行董事長，並引入了行業資深專業人士如 Stephen Devine 加入董事會。這一領導層的更新有望在競爭壓力中激勵 FINEOS 的發展軌跡，可能加速其實現正現金流和超越市場表現的進程。</p>
</div><ul>
<li>Click here and access our complete health analysis report to understand the dynamics of FINEOS Corporation Holdings.</li>
<li>Learn about FINEOS Corporation Holdings' historical performance.</li>
</ul>
<div class="lb-trans"><ul>
<li>點擊這裏訪問我們的完整健康分析報告，以瞭解 FINEOS Corporation Holdings 的動態。</li>
<li>瞭解 FINEOS Corporation Holdings 的歷史表現。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/e94d8063-92b0-4417-ae8a-08facdd76595/chart/revenue-and-expenses-breakdown" alt="" original-src="https://images.simplywall.st/company/e94d8063-92b0-4417-ae8a-08facdd76595/chart/revenue-and-expenses-breakdown"/></p>
<p>ASX:FCL Revenue and Expenses Breakdown as at Dec 2025</p>
<div class="lb-trans"><p>截至 2025 年 12 月的 ASX:FCL 收入和支出明細</p>
</div><h2>PYC Therapeutics (ASX:PYC)</h2>
<div class="lb-trans"><h2>PYC Therapeutics (ASX:PYC)</h2>
</div><p><strong>Simply Wall St Growth Rating:</strong> ★★★★☆☆</p>
<div class="lb-trans"><p><strong>Simply Wall St 增長評級：</strong> ★★★★☆☆</p>
</div><p><strong>Overview:</strong> PYC Therapeutics Limited is a drug-development company focused on creating RNA-based treatments for genetic diseases in Australia, with a market cap of A$956.55 million.</p>
<div class="lb-trans"><p><strong>概述：</strong> PYC Therapeutics Limited 是一家藥物開發公司，專注於為澳大利亞的遺傳疾病開發基於 RNA 的治療，其市值為 9.5655 億澳元。</p>
</div><p><strong>Operations:</strong> The company generates revenue through its focus on the discovery and development of novel RNA therapeutics, with reported revenue of A$23.49 million.</p>
<div class="lb-trans"><p><strong>運營：</strong> 該公司通過專注於新型 RNA 治療的發現和開發來產生收入，報告收入為 2349 萬澳元。</p>
</div><p>PYC Therapeutics, navigating through a challenging phase with expected revenue contraction of 5.8% annually over the next three years, remains optimistic about its future profitability, projecting an earnings growth of 27.6% per annum. This contrasts starkly with its current unprofitability and shareholder dilution experienced last year. Recent strategic board changes, including the appointment of Peter Coleman as Independent Non-Executive Chair, underscore a commitment to leveraging his M&amp;A expertise to steer PYC towards anticipated robust returns on equity of 22.8%. These moves are pivotal as PYC aims to reverse negative trends and capitalize on growth opportunities in the biotech sector.</p>
<div class="lb-trans"><p>PYC Therapeutics 在經歷了一個充滿挑戰的階段，預計未來三年收入將年縮減 5.8%，但對未來盈利仍持樂觀態度，預計年盈利增長為 27.6%。這與其當前的虧損狀態和去年經歷的股東稀釋形成鮮明對比。最近的戰略董事會變動，包括任命 Peter Coleman 為獨立非執行主席，強調了利用其併購專業知識引導 PYC 實現預期的 22.8% 強勁股本回報的承諾。這些舉措對 PYC 逆轉負面趨勢並在生物科技領域抓住增長機會至關重要。</p>
</div><ul>
<li>Unlock comprehensive insights into our analysis of PYC Therapeutics stock in this health report.</li>
<li>Gain insights into PYC Therapeutics' past trends and performance with our Past report.</li>
</ul>
<div class="lb-trans"><ul>
<li>在這份健康報告中解鎖我們對 PYC Therapeutics 股票分析的全面見解。</li>
<li>通過我們的歷史報告獲取 PYC Therapeutics 的過去趨勢和表現的見解。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/3e24207c-efd2-40eb-8d28-87ef9ac565d7/chart/earnings-and-revenue-growth" alt="" original-src="https://images.simplywall.st/company/3e24207c-efd2-40eb-8d28-87ef9ac565d7/chart/earnings-and-revenue-growth"/></p>
<p>ASX:PYC Earnings and Revenue Growth as at Dec 2025</p>
<div class="lb-trans"><p>截至 2025 年 12 月的 ASX:PYC 盈利和收入增長</p>
</div><h2>RPMGlobal Holdings (ASX:RUL)</h2>
<div class="lb-trans"><h2>RPMGlobal Holdings (ASX:RUL)</h2>
</div><p><strong>Simply Wall St Growth Rating:</strong> ★★★★☆☆</p>
<div class="lb-trans"><p><strong>Simply Wall St 增長評級：</strong> ★★★★☆☆</p>
</div><p><strong>Overview:</strong> RPMGlobal Holdings Limited develops and provides mining software solutions across various regions including Australia, Asia, the Americas, Africa, and Europe with a market capitalization of approximately A$1.10 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> RPMGlobal Holdings Limited 開發並提供礦業軟件解決方案，覆蓋澳大利亞、亞洲、美洲、非洲和歐洲等多個地區，市值約為 11 億澳元。</p>
</div><p><strong>Operations:</strong> RPMGlobal Holdings generates revenue primarily through its Software segment, accounting for A$73.96 million, while the Advisory segment contributes A$24.77 million.</p>
<div class="lb-trans"><p><strong>運營：</strong> RPMGlobal Holdings 主要通過其軟件部門產生收入，金額為 7396 萬澳元，而諮詢部門貢獻 2477 萬澳元。</p>
</div><p>RPMGlobal Holdings, with a projected annual revenue growth of 15% and earnings surge of 55%, outpaces the Australian market averages significantly. Despite a minor profit margin contraction to 0.01% from last year's 5.3%, the company's strategic focus on innovative software solutions in mining could drive future profitability. A recent shareholder meeting highlighted an approval scheme with Caterpillar, potentially enhancing RPMGlobal's market position and operational scope, marking it as a noteworthy contender in Australia’s tech landscape despite some financial volatility marked by one-off losses totaling A$2.2M last fiscal year.</p>
<div class="lb-trans"><p>RPMGlobal Holdings 預計年收入增長 15%，盈利激增 55%，顯著超過澳大利亞市場平均水平。儘管利潤率從去年的 5.3% 小幅收縮至 0.01%，但該公司對礦業創新軟件解決方案的戰略關注可能推動未來盈利。最近的股東會議強調了與 Caterpillar 的批准計劃，可能增強 RPMGlobal 的市場地位和運營範圍，使其在澳大利亞科技領域成為一個值得關注的競爭者，儘管去年財務波動中出現了 220 萬澳元的一次性損失。</p>
</div><ul>
<li>Click here to discover the nuances of RPMGlobal Holdings with our detailed analytical health report.</li>
<li>Evaluate RPMGlobal Holdings' historical performance by accessing our past performance report.</li>
</ul>
<div class="lb-trans"><ul>
<li>點擊這裏通過我們的詳細分析健康報告發現 RPMGlobal Holdings 的細微差別。</li>
<li>通過訪問我們的歷史表現報告評估 RPMGlobal Holdings 的歷史表現。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/ab8df570-d416-497d-a9f1-5b7dd287a345/chart/earnings-and-revenue-growth" alt="" original-src="https://images.simplywall.st/company/ab8df570-d416-497d-a9f1-5b7dd287a345/chart/earnings-and-revenue-growth"/></p>
<p>ASX:RUL Earnings and Revenue Growth as at Dec 2025</p>
<div class="lb-trans"><p>ASX:RUL 截至 2025 年 12 月的收益和收入增長</p>
</div><h2>Next Steps</h2>
<div class="lb-trans"><h2>下一步</h2>
</div><ul>
<li>Gain an insight into the universe of 22 ASX High Growth Tech and AI Stocks by clicking here.</li>
<li>Have you diversified into these companies? Leverage the power of Simply Wall St's portfolio to keep a close eye on market movements affecting your investments.</li>
<li>Enhance your investing ability with the Simply Wall St app and enjoy free access to essential market intelligence spanning every continent.</li>
</ul>
<div class="lb-trans"><ul>
<li>點擊這裏深入瞭解 22 只 ASX 高增長科技和人工智能股票的全貌。</li>
<li>你是否已經將投資組合多樣化到這些公司？利用 Simply Wall St 的投資組合功能，密切關注影響你投資的市場動態。</li>
<li>使用 Simply Wall St 應用程序提升你的投資能力，享受免費訪問覆蓋每個大洲的市場情報。</li>
</ul>
</div><h2>Interested In Other Possibilities?</h2>
<div class="lb-trans"><h2>對其他可能性感興趣？</h2>
</div><ul>
<li>Explore high-performing small cap companies that haven't yet garnered significant analyst attention.</li>
<li>Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.</li>
<li>Find companies with promising cash flow potential yet trading below their fair value.</li>
</ul>
<div class="lb-trans"><ul>
<li>探索尚未獲得顯著分析師關注的高表現小型公司。</li>
<li>用顯示強勁增長潛力的公司充實你的投資組合，這些公司得到了分析師和管理層的樂觀展望支持。</li>
<li>尋找現金流潛力良好但交易價格低於其公允價值的公司。</li>
</ul>
</div><p><em>This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.</em></p>
<div class="lb-trans"><p><em>這篇文章由 Simply Wall St 撰寫，內容具有一般性。<strong>我們提供基於歷史數據和分析師預測的評論，僅使用無偏見的方法，我們的文章並不構成財務建議。</strong> 它不構成買入或賣出任何股票的推薦，也未考慮你的目標或財務狀況。我們的目標是為你提供以基本數據驅動的長期分析。請注意，我們的分析可能未考慮最新的價格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中沒有持倉。</em></p>
</div><p>Mobile Infrastructure for Defense and Disaster</p>
<div class="lb-trans"><p>移動基礎設施用於國防和災難</p>
</div><p>The next wave in robotics isn't humanoid. Its fully autonomous towers delivering 5G, ISR, and radar in under 30 minutes, anywhere.</p>
<div class="lb-trans"><p>下一波機器人技術不是類人型的。它是完全自主的塔樓，在 30 分鐘內提供 5G、ISR 和雷達服務，覆蓋任何地方。</p>
</div><p>Get the investor briefing before the next round of contracts</p>
<div class="lb-trans"><p>在下一輪合同之前獲取投資者簡報</p>
</div><p>Sponsored On Behalf of CiTech</p>
<div class="lb-trans"><p>代表 CiTech 贊助</p>
</div>

探索澳大利亞高增長科技股，重點介紹三家知名企業